HBV'de Tedavi - EKMUD

3. Bodey GB, Buckley M, Sahte YS, Freireich EJ. Quantitative
relationships between circulating leukocytes and infection
in patients with acute leukemia. Ann Intern Med
1966;64:328-40.
4. Bodey GP, Rolston KVI. Management of fever in neutropenic
patients. J Infect Chemother 2001;7:1-9.
5. Cleary JF. Fever and sweats: including the immunocompromised
hosts. In: Berger A, Portenoy RK, Weissman DE
(eds). Principles and Practice of Supportive Oncology.
Philadelphia: Lippincott-Raven Publishers, 1998:119-31.
6. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice
guideline for the use of antimicrobial agents in neutropenic
patients with cancer: 2010 update by Infectious
Diseases Society of America. Clin Infect Dis 2011;52:e56e93,
doi:10.1093/cid/cir073.
Serpil Erol
7. Sakr Y, Tuche SF, Reinhart BK. The role of procalcitonin in
febril neutropenic patients: review of literature. Infection
2008:396-47.
8. Serody JS, Kelley M, Cohen MS. Infection in the immunocompromised
host. In: Brilmann C, Quenzer RW (eds).
Infectious Diseases in Emergency Medicine. 2 nd ed.
Philadelphia: Little Brown, 1998:317-37.
9. Sudhoff T, Giagounidis A, Karthaus M. Serum and plasma
parameters in clinical evaluation of neutropenic fever.
Antibiot Chemother 2000;50:10-9.
3. Türkiye EKMUD Bilimsel Platformu 165